Rational engineering of an improved adenosine deaminase 2 enzyme for weaponizing T-cell therapies [0.03%]
改进型腺苷脱氨酶2的理性工程以增强T细胞疗法的效果
J R Cox,M Jennings,C Lenahan et al.
J R Cox et al.
Adenosine is a potent immunosuppressive metabolite that accumulates in the extracellular space within solid tumors and inhibits the antitumor function of native immune cell responses as well as chimeric antigen receptor (CAR) T-cell therapi...
Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors [0.03%]
工程化嵌合抗原受体T细胞治疗实体瘤的研究
A Neeser,R Ramasubramanian,C Wang et al.
A Neeser et al.
The early clinical success and subsequent US Food and Drug Administration approval of chimeric antigen receptor (CAR)-T cell therapy for leukemia and lymphoma affirm that engineered T cells can be a powerful treatment for hematologic malign...
Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond [0.03%]
着眼黑色素瘤免疫治疗：Tebentafusp及其后疗法
C Gerard,B Shum,P Nathan et al.
C Gerard et al.
Uveal melanoma (UM) is the most common ocular malignancy in adults, associated with the poorest prognosis, with metastatic disease occurring in up to 50% of patients. In contrast to metastatic cutaneous melanoma, the use of immune checkpoin...
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors [0.03%]
IOA-289（一种新型自分泌运动因子抑制剂）的表征及其在实体肿瘤治疗中的转化研究
M A Deken,K Niewola-Staszkowska,O Peyruchaud et al.
M A Deken et al.
Background: Autotaxin-lysophosphatidic acid (ATX-LPA) signaling has a predominant role in immunological and fibrotic processes, including cancer. Several ATX inhibitors and LPA receptor antagonists have been clinically ev...
M Nabhan,D Egan,M Kreileder et al.
M Nabhan et al.
Immune checkpoint inhibitors (ICIs) have rejuvenated therapeutic approaches in oncology. Although responses tend to be durable, response rates vary in many cancer types. Thus, the identification and validation of predictive biomarkers is a ...
H Balke-Want,V Keerthi,A Cadinanos-Garai et al.
H Balke-Want et al.
Chimeric antigen receptor (CAR) T cell therapy has made significant strides in the treatment of B-cell malignancies, but its application in treating solid tumors still poses significant challenges. Particularly, the widespread use of viral ...
Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors [0.03%]
免疫检查点抑制剂治疗后原发性和继发性肾上腺功能不全相关的自身抗体
N C Helderman,M W Lucas,C U Blank
N C Helderman
Primary and secondary adrenal insufficiency (AI) are commonly known immune-related adverse events following treatment with immune checkpoint inhibitors (ICIs), and are clinically relevant due to their morbidity and potential mortality. For ...
Á F Sanromán,K Joshi,L Au et al.
Á F Sanromán et al.
•T-cell receptor (TCR) interaction with major histocompatibility complex-antigen complexes leads to antitumour responses.•TCR sequencing analysis allows characterisation of T cells that recognise tumour neoantigens.•T-cell clonal revival...